A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Dec 2017

At a glance

  • Drugs Macitentan (Primary)
  • Indications Portal hypertension; Pulmonary hypertension
  • Focus Therapeutic Use
  • Acronyms PORTICO
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 11 Dec 2017 Planned End Date changed from 20 Feb 2018 to 22 Jan 2018.
    • 21 Nov 2017 This trial has been completed in Germany.
    • 01 Sep 2017 Planned End Date changed from 15 Mar 2018 to 20 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top